Filter Results
:
(1,197)
Show Results For
-
All HBS Web
(1,197)
- People (5)
- News (330)
- Research (691)
- Events (1)
- Multimedia (16)
- Faculty Publications (441)
Show Results For
-
All HBS Web
(1,197)
- People (5)
- News (330)
- Research (691)
- Events (1)
- Multimedia (16)
- Faculty Publications (441)
- October 2009 (Revised August 2014)
- Case
Tengion: Bringing Regenerative Medicine to Life
By: Elie Ofek and Polly Ross Ribatt
Tengion is a young biotech company that is at the frontier of regenerative medicine—a nascent field that seeks to promote the creation of new cells and tissue to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. In late...
View Details
Keywords:
Decision Choices and Conditions;
Financial Crisis;
Entrepreneurship;
Health Care and Treatment;
Technological Innovation;
Product Launch;
Product Development;
Research and Development;
Biotechnology Industry;
United States
Ofek, Elie, and Polly Ross Ribatt. "Tengion: Bringing Regenerative Medicine to Life." Harvard Business School Case 510-031, October 2009. (Revised August 2014.)
- 22 Feb 2024
- News
Combat-Tested Cancer Coaching
Subscribe on iTunes Subscribe on Spotify More Skydeck episodes Hi, this is Dan Morrell, host of Skydeck. When Kathy Giusti (MBA 1985) was diagnosed with multiple myeloma in 1996, she was overwhelmed. It was the pre-Internet era, with limited available information, but...
View Details
- 07 May 2009
- Working Paper Summaries
Broadening Focus: Spillovers and the Benefits of Specialization in the Hospital Industry
- April 2017
- Supplement
Imprimis (C)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A & B). Set in 2015, it first describes Imprimis’s decision to introduce its own line of compounded eye drop medication called LessDrops. The case then examines the moral dilemma faced by CEO Mark Baum, who was struck by the...
View Details
Keywords:
Health Care and Treatment;
Cost;
Moral Sensibility;
Competitive Strategy;
Decision Choices and Conditions;
Pharmaceutical Industry;
United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (C)." Harvard Business School Supplement 717-497, April 2017.
- August 2024
- Article
How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?
By: Leemore S. Dafny, Kate Ho and Edward Kong
Drug copayment coupons to reduce patient cost-sharing have become nearly ubiquitous for high-priced brand-name prescription drugs. Medicare bans such coupons on the grounds that they are kickbacks that induce utilization, but they are commonly used by...
View Details
Keywords:
Prescription Drugs;
Coupons;
Impact;
Health Care and Treatment;
Markets;
Price;
Spending;
Pharmaceutical Industry;
United States
Dafny, Leemore S., Kate Ho, and Edward Kong. "How Do Copayment Coupons Affect Branded Drug Prices and Quantities Purchased?" American Economic Journal: Economic Policy 16, no. 3 (August 2024): 314–346.
- 02 Mar 2007
- What Do You Think?
What Is the Government’s Role in US Health Care?
argued that "Containing costs will come at the expense of something technological advances, profit, access to certain services, and patient choice are likely candidates ." One line of thinking would make both talent and drugs more...
View Details
- 22 Mar 2021
- Research & Ideas
How to Learn from the Big Mistake You Almost Make
What if businesses could learn from their worst mistakes without actually making them? How might the same progress and innovation occur, without firms incurring the costs associated with such errors? The results of a recent study about close calls in health View Details
- 01 Mar 2024
- News
Vital Signs
day. An abbreviation of “demonstrating diagnostics,” DemDx is a software platform with embedded AI technology that guides health care providers through all the necessary questions in a patient examination to...
View Details
- Web
Finance - Faculty & Research
the health care industry. The preponderance of evidence indicates that some PE investments have resulted in increased costs of care and some negative changes in quality of care, as indicated by View Details
- 23 Jan 2008
- First Look
First Look: January 23, 2008
for Integration of Medicine and Innovative Technology (CIMIT) Harvard Business School Case 608-036 Translating innovative ideas form the clinician to the patient remains a major problem in the field of medicine. Dr. John Parrish and...
View Details
Keywords:
Martha Lagace
- Web
What is FIELD Global Immersion? - MBA
medical care for patients in Brazil. Once projects are proposed by potential Global Partners, the Global Partner team works closely with FGI faculty to select the projects that have the most promise in...
View Details
- 01 Dec 2023
- News
Joint Venture
The human knee is a marvel. It’s the hinge at the center of our gait, the evolutionary adaptation that makes humans the only fully bipedal mammals on the planet. But the knee also is a complicated and vulnerable knot of bone, muscle, and sinew. Nearly everyone knows...
View Details
Keywords:
Shoshi Parks
- 2023
- Article
Building the Business Case for an Inclusive Approach to Digital Health Measurement with a Web App (Market Opportunity Calculator): Instrument Development Study
By: Mitchell Tang, Yashoda Sharma, Jennifer C. Goldsack and Ariel Dora Stern
Background: The use of digital health measurement tools has grown substantially in recent years. However, there are concerns that the promised benefits from these products will not be shared equitably. Underserved populations, such as those with lower education and...
View Details
Keywords:
Demographics;
Product Development;
Health Care and Treatment;
Medical Devices and Supplies Industry
Tang, Mitchell, Yashoda Sharma, Jennifer C. Goldsack, and Ariel Dora Stern. "Building the Business Case for an Inclusive Approach to Digital Health Measurement with a Web App (Market Opportunity Calculator): Instrument Development Study." JMIR Formative Research 7 (2023).
- Web
Aligning Reimbursement with Value - Institute For Strategy And Competitiveness
Measure Outcomes & Cost for Every Patient Aligning Reimbursement with Value Systems Integration Geography of Care Information Technology Aligning Reimbursement w... Aligning Reimbursement with Value...
View Details
- 14 Jul 2023
- Blog Post
Harvard Business School Announces Its 2023-2024 Blavatnik Fellows
scientist at Harvard-affiliated Brigham and Women’s Hospital; she also cares for many patients with complex chronic disease that can be treated with exercise and conducts research on innovative approaches to...
View Details
- Web
Video Clips - Creating Emerging Markets
for patients in their rehabilitation center as well as children at their school, the Institution Tahar Sebti. Duration: 04:36 Suresh Krishna Suresh Krishna Base Of The Pyramid Suresh Krishna, founder of the largest manufacturer of...
View Details
- Web
Publications - Institute For Strategy And Competitiveness
“inpatient-only list” in January 2022. An additional 1,500 surgeries will be eliminated in the following year. The change... 01 Feb 2021 Health Care Measurements that Improve Patient Outcomes by Robert S....
View Details
- May 2011
- Article
Nonsimultaneous Chains and Dominos in Kidney Paired Donation—Revisited
By: Itai Ashlagi, Duncan S. Gilchrist, Alvin E. Roth and Michael A. Rees
Since 2008 kidney exchange in America has grown in part from the incorporation of non-directed donors in transplant chains rather than simple exchanges. It is controversial whether these chains should be performed simultaneously ("domino paired donation," DPD) or...
View Details
Keywords:
ABO Incompatibility;
Allosensitization;
Paired Kidney Exchange;
Regional Sharing;
Simulation Models;
Transplantation Policy;
Health Care and Treatment;
Supply Chain;
Risk and Uncertainty;
Logistics;
United States
Ashlagi, Itai, Duncan S. Gilchrist, Alvin E. Roth, and Michael A. Rees. "Nonsimultaneous Chains and Dominos in Kidney Paired Donation—Revisited." American Journal of Transplantation 11, no. 5 (May 2011): 984–994.
- 14 Jul 2009
- First Look
First Look: July 14
horizontal preferences, distinct segments exist—each caring about innovation on only one attribute—and firms are a priori uncertain how many consumers each segment contains. In this case, a firm that conducts market research may follow a...
View Details
Keywords:
Martha Lagace
- 2021
- Working Paper
Regulatory Approval and Expanded Market Size
By: Benjamin Berger, Amitabh Chandra and Craig Garthwaite
Regulatory review of new medicines is often viewed as a hindrance to innovation by increasing the hurdle to bring products to market. However, a more complete accounting of regulation must also account for its potential market expanding effects through quality...
View Details
Keywords:
New Medicines;
Regulatory Approval;
Health Care and Treatment;
Research and Development;
Governing Rules, Regulations, and Reforms;
Markets;
Expansion;
Pharmaceutical Industry
Berger, Benjamin, Amitabh Chandra, and Craig Garthwaite. "Regulatory Approval and Expanded Market Size." NBER Working Paper Series, No. 28889, June 2021.